BML Capital Management, LLC
13F Reported Value
ⓘ$176.1M
incl. option notional
Equity Holdings
ⓘ$175.1M
Option Notional
ⓘ$954,088
$954,088 puts / $0 calls
Holdings
18
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
BML Capital Management, LLC disclosed 18 positions worth $176.1M in its Form 13F-HR for Q2 2026 — $175.1M in common stock plus $954,088 of put/call option positions (reported at underlying notional value, not premium at risk), led by $ACRS (Aclaris Therapeutics, Inc.) at 36.2% of the equity portfolio, followed by $AVIR and $ENGN. During the quarter the fund opened 3 new positions and exited 1 — including a new stake in $ENGN and a full exit from $KZR. The portfolio is most concentrated in Healthcare (80.6% of disclosed assets). All figures are sourced directly from BML Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1616824.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 12.0#2,892
Quality
$63.3M11,975,000 sh - —
Quality
$32.3M6,952,330 sh - —
Quality
$11.5M6,669,908 sh - 47.0
Quality
$11.0M465,000 sh - 18.5
Quality
$10.9M2,519,701 sh - 50.0
Quality
$9.1M172,500 sh - 46.4
Quality
$9.0M2,150,000 sh - —
Quality
$7.1M5,330,000 sh - 30.0
Quality
$5.0M645,600 sh - 60.7
Quality
$4.9M37,500 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Aclaris Therapeutics, Inc.$ACRS | 12.0#2,892 | $63.3M | 11,975,000 |
 Atea Pharmaceuticals, Inc.$AVIR | — | $32.3M | 6,952,330 |
 enGene Therapeutics Inc.$ENGN | — | $11.5M | 6,669,908 |
 Kraft Heinz Co$KHC | 47.0 | $11.0M | 465,000 |
 Outset Medical, Inc.$OM | 18.5 | $10.9M | 2,519,701 |
 CARMAX INC$KMX | 50.0 | $9.1M | 172,500 |
 TILLY'S, INC.$TLYS | 46.4 | $9.0M | 2,150,000 |
 PMV Pharmaceuticals, Inc.$PMVP | — | $7.1M | 5,330,000 |
 Instil Bio, Inc.$TIL | 30.0 | $5.0M | 645,600 |
 TARGET CORP$TGT | 60.7 | $4.9M | 37,500 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of BML Capital Management, LLC's 18 positions.
Showing top 10 of 18 holdings.
Sector Allocation
Healthcare
$141.1M
Consumer Discretionary
$23.1M
Consumer Staples
$11.0M
Full Holdings — BML Capital Management, LLC (Q2 2026)
All 18 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ACRS | Aclaris Therapeutics, Inc. | $63.3M | 36.2% | -16% | 12 |
| 2 | $AVIR | Atea Pharmaceuticals, Inc. | $32.3M | 18.5% | -2% | — |
| 3 | $ENGN | enGene Therapeutics Inc. | $11.5M | 6.6% | NEW | — |
| 4 | $KHC | Kraft Heinz Co | $11.0M | 6.3% | +272% | 47 |
| 5 | $OM | Outset Medical, Inc. | $10.9M | 6.2% | +32% | 18.5 |
| 6 | $KMX | CARMAX INC | $9.1M | 5.2% | +11% | 50 |
| 7 | $TLYS | TILLY'S, INC. | $9.0M | 5.2% | +0% | 46.4 |
| 8 | $PMVP | PMV Pharmaceuticals, Inc. | $7.1M | 4.1% | +0% | — |
| 9 | $TIL | Instil Bio, Inc. | $5.0M | 2.8% | +0% | 30 |
| 10 | $TGT | TARGET CORP | $4.9M | 2.8% | +0% | 60.7 |
| 11 |  $ORMP | ORAMED PHARMACEUTICALS INC. | $4.2M | 2.4% | -73% | 44.4 |
| 12 |  $JANX | Janux Therapeutics, Inc. | $2.4M | 1.4% | +0% | 30.1 |
| 13 |  $PLRX | PLIANT THERAPEUTICS, INC. | $1.8M | 1.0% | +0% | — |
| 14 |  $CNTB | Connect Biopharma Holdings Ltd | $1.4M | 0.8% | +40% | — |
| 15 |  $IMA | ImageneBio, Inc. | $1.2M | 0.7% | +0% | 6.6 |
| 16 |  $WMTPUT | Walmart Inc. | $386,088 | — | +0% | 60.2 |
| 17 |  $CORZPUT | Core Scientific, Inc./tx | $298,000 | — | NEW | 14.1 |
| 18 |  $TSLAPUT | Tesla, Inc. | $270,000 | — | NEW | 53.9 |
New Positions (3)
Exited Positions (1)
$KZR Kezar Life Sciences, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for BML Capital Management, LLC including:
Track BML Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for BML Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: BML Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For BML Capital Management, LLC (SEC CIK: 1616824), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in BML Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.